WaveMan
WaveMan · Company
AXGN · Axogen, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AXGN Axogen (AXGN) Insider Trading, Ownership & Congress Trades

Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0000805928
Quote by TradingView
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
166
13F, latest reported quarter
Conversions, 180 days
14
Codes C/M, not in net · $1.0M priced

What the filings say about AXGN

Insiders, 180 days
-$6.3M net sold
8 sellers · 9% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$4.6M
4 notices

Axogen insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Axogen, Inc. insiders sold a net $6.3M of stock across 102 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
TYNDALL JOSEPH A.
Director
SELL
2026-09-04 SECtraded 2026-09-02
3,500
$173.9K
-19.8%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (1 buy, 6 sales), the last on Dec 9, 2025.
  • The trade is 32.9% of the 10,650 shares held after it.
  • 3 other insiders sold within 30 days.
  • 166 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director TYNDALL JOSEPH A. sold about $173.9K of AXGN under a 10b5-1 plan on Sep 2, 2026; 3 other insiders sold within 30 days and 166 funds added in the latest 13F quarter.
Wendell Amy McBride
Director
SELL
2026-08-12 SECtraded 2026-08-11
13,353
$646.6K
-22.0%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (1 buy, 6 sales), the last on May 8, 2026.
  • The trade is 12.4% of the 107,976 shares held after it.
  • 3 other insiders sold within 30 days.
  • 166 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wendell Amy McBride sold about $646.6K of AXGN on Aug 11, 2026; 3 other insiders sold within 30 days and 166 funds added in the latest 13F quarter.
Began Marc A
EVP & General Counsel
SELL
2026-08-12 SECtraded 2026-08-10
67,500
$3.2M
-22.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Dec 11, 2025.
  • The trade is 134.6% of the 50,135 shares held after it.
  • 3 other insiders sold within 30 days.
  • 166 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & General Counsel Began Marc A sold about $3.2M of AXGN on Aug 10, 2026, the largest insider sale at the company on our record; 3 other insiders sold within 30 days and 166 funds added in the latest 13F quarter.
Weiler Kathy Johnson
Director
SELL
2026-08-11 SECtraded 2026-08-07
14,150
$641.0K
-24.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on May 7, 2026.
  • 3 other insiders sold within 30 days.
  • 166 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Weiler Kathy Johnson sold about $641.0K of AXGN on Aug 7, 2026; 3 other insiders sold within 30 days and 166 funds added in the latest 13F quarter.
Wendell Amy McBride
Director
SELL
2026-05-12 SECtraded 2026-05-08
1,647
$70.2K
-7.0%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (1 buy, 5 sales), the last on Dec 16, 2025.
  • The trade is 1.8% of the 93,826 shares held after it.
  • 5 other insiders sold within 30 days.
  • 166 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wendell Amy McBride sold about $70.2K of AXGN on May 8, 2026; 5 other insiders sold within 30 days and 166 funds added in the latest 13F quarter.
102 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 97 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$6.3M over 180 days
-$4.7M over 90 days
below 80% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
166 funds bought in last quarter
more than 78% of Medical Devices
Revenue
+20.2% year over year
more than 72% of Medical Devices
Margin
-7.0% net margin
more than 60% of Medical Devices
Buybacks
no share repurchases reported
Short interest
9.6% of the float short (float per yahoo 2026-10-26) · 4.2 days to cover · settled 2026-09-30
more than 83% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AXGN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+107.5%12M
-2%+61%+124%+187%2025-102025-122026-022026-042026-062026-082026-10 2026-08-10 · Began Marc A sold $3.2M2025-12-09 · DALE MICHAEL D sold $1.9M2025-12-10 · DALE MICHAEL D sold $750.0K2026-05-07 · Weiler Kathy Johnson sold $720.6K2026-08-11 · Wendell Amy McBride sold $646.6K2025-12-16 · Weiler Kathy Johnson sold $644.9K2026-08-07 · Weiler Kathy Johnson sold $641.0K2025-12-09 · THOMAS PAUL sold $633.6K2025-12-09 · DeVinney Erick Wayne sold $609.1K2025-12-16 · Wendell Amy McBride sold $599.0K2025-12-16 · Weiler Kathy Johnson sold $539.2K2025-12-16 · Wendell Amy McBride sold $534.8K2026-05-07 · JOHNSON JOHN sold $478.0K2025-11-10 · Burke William P. Mr. sold $461.6K2025-12-15 · Hartley Lindsey Marie sold $442.3K2025-12-09 · TYNDALL JOSEPH A. sold $441.4K2025-10-29 · Burke William P. Mr. sold $435.6K2025-10-30 · Burke William P. Mr. sold $419.7K2025-12-11 · Began Marc A sold $396.7K2025-12-09 · JOHNSON JOHN sold $394.0K2025-10-29 · Burke William P. Mr. sold $391.3K2025-12-08 · JOHNSON JOHN sold $371.2K2025-12-08 · JOHNSON JOHN sold $368.9K2025-12-08 · Hartley Lindsey Marie sold $364.0K2025-12-09 · TYNDALL JOSEPH A. sold $336.4K2025-12-09 · Began Marc A sold $289.6K2025-11-05 · Burke William P. Mr. sold $274.9K2025-12-09 · JOHNSON JOHN sold $256.2K2025-12-09 · Kemp Jens sold $254.5K2025-12-16 · Weiler Kathy Johnson sold $194.4K2026-09-02 · TYNDALL JOSEPH A. sold $173.9K2026-05-07 · Kemp Jens sold $173.8K2026-03-16 · DeVinney Erick Wayne sold $171.5K2026-05-07 · Quackenbush Doris sold $168.7K2025-12-16 · Wendell Amy McBride sold $146.6K2025-11-06 · Burke William P. Mr. sold $128.4K2025-12-08 · Hartley Lindsey Marie sold $90.1K2025-11-11 · Burke William P. Mr. sold $86.3K2026-05-08 · Wendell Amy McBride sold $70.2K2026-05-07 · Hartley Lindsey Marie sold $25.0K2026-05-07 · Hartley Lindsey Marie sold $20.9K2026-09-02 · JOSEPH A TYNDALL filed to sell $174.6K2026-08-11 · AMY MCBRIDE-WENDELL filed to sell $643.9K2026-08-10 · MARC BEGAN filed to sell $3.1M2026-08-07 · KATHY WEILER filed to sell $627.6K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AXGN: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
4,419,208 sh
$204.1M
First Light Asset Management, LLC
2,748,361 sh
$126.9M
MORGAN STANLEY
2,747,924 sh
$126.9M
VANGUARD CAPITAL MANAGEMENT LLC
2,257,948 sh
$104.3M
Assenagon Asset Management S.A.
2,087,300 sh
$96.4M

Congress trades in AXGN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AXGN planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
JOSEPH A TYNDALL
Filed 2026-09-02
$174.6K
AMY MCBRIDE-WENDELL
Filed 2026-08-11
$643.9K
MARC BEGAN
Filed 2026-08-10
$3.1M
KATHY WEILER
Filed 2026-08-07
$627.6K

AXGN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Meridian Small Cap Growth Fund
$8.7M position · as of 2026-06-30
3.2%
Brown Capital Management Small Company Fund
$8.3M position · as of 2026-06-30
2.6%
Meridian Growth Fund
$13.2M position · as of 2026-06-30
2.4%
RiverPark/Next Century Growth Fund
$287.1K position · as of 2026-06-30
2.4%
Wasatch Micro Cap Value Fund
$8.8M position · as of 2026-06-30
2.3%
Invesco Dorsey Wright Healthcare Momentum ETF
$4.8M position · as of 2026-07-31
2.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 3
0 active
2
Phase 4
1 active
6
Not applicable
2 active
What changed recently
Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression
2026-10-14 · Active Not Recruiting → Completed
Not applicable
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $6.3M sold by insiders over 180 days, 166 funds added last quarter, $4.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

AXGN financials

Revenue growth
+20.2%
XBRL, annual
Net margin
-7.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$251.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-13.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$8.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.01x
long-term 2026-06-30 plus current 2020-09-30 (69 months older than the period end); equity 2026-06-30
Cash flow to debt
6.02x
TTM operating cash flow over long-term 2026-06-30 plus current 2020-09-30 (69 months older than the period end)
Return on equity
-18.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-13.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-5.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.9B
market value at close 2026-10-27 on 2026-07-27 shares, plus long-term 2026-06-30 plus current 2020-09-30 (69 months older than the period end), minus cash 2026-06-30
FCF yield
+0.4%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$225.2M$187.3M$159.0M$138.6M
Gross profit$167.4M$142.0M$121.9M$108.8M
Operating income-$7.8M-$3.3M-$21.5M-$29.7M
Net income-$15.7M-$10.0M-$21.7M-$28.9M
EPS (diluted)-0.34-0.23-0.51-0.69
Operating cash flow$812.0K$4.5M-$5.7M-$16.1M
Cash$35.5M$27.6M$31.0M$15.3M
Long-term debt$48.4M$47.5M$46.6M$45.7M
SEC XBRL, fiscal years, as known on 2026-10-28

AXGN Stock Sonar score 6/7 axes

Find similar shapesCompare

AXGN ranks highest on financial health (92nd percentile) and growth (72nd), and lowest on insider conviction (9th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
55
Inputs
  • Return on equity-18.2% · 53 pct, sector of 183
  • Return on assets-13.1% · 52 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-5.6% · 61 pct, sector of 188
Financial health
92
Inputs
  • Debt to equity0.01x · 86 pct, sector of 159
  • Cash flow to debt6.02x · 97 pct, sector of 150
Growth
72
Inputs
  • Revenue growth, YoY+20.2% · 72 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
9
Inputs
  • Net Form 4 buying (codes P and S), 180d-$6.1M · 18 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
52
Inputs
  • Funds adding, latest quarter166 · 78 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$120K · 27 pct, sector of 50
Risk and compliance
47
Inputs
  • Short interest, % of float+9.6% · 23 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+20.1% · 19 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AXGN filings, in plain words

Are Axogen insiders buying or selling AXGN?

In the 180 days to 2026-10-28, Axogen insiders were net sellers, a net $6.3M across purchases and sales reported on Form 4, by 8 sellers.

Are there planned insider sales of AXGN?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $4.6M of stock; the latest, by JOSEPH A TYNDALL, was filed 2026-09-02.

Read the full summary

In the 180 days to 2026-10-28, Axogen insiders were net sellers of AXGN, a net $6.3M across purchases and sales reported on Form 4 by 8 sellers. 9% of the 11 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $4.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies